Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Haloperidol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 15/20 | 0.80 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.80 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 0.80 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.80 |
| ▸ | HTR1A | P08908 | 3/20 | 0.80 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.80 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.80 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.80 |
| ▸ | HRH1 | P35367 | 3/20 | 0.80 |
| ▸ | HTR2C | P28335 | 2/20 | 0.80 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.80 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.80 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Haloperidol SCHEMBL41057 | 1.00 | DRD2 (0.80) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Haloperidol SCHEMBL19463557 | 1.00 | DRD2 (0.80) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Haloperidol SCHEMBL28595609 | 0.99 | DRD2 (0.78) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Haloperidol SCHEMBL10392879 | 0.95 | DRD2 (0.72) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Haloperidol SCHEMBL5452448 | 0.95 | DRD2 (0.72) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Haloperidol SCHEMBL10392880 | 0.95 | DRD2 (0.72) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Bromperidol SCHEMBL27681710 | 0.91 | DRD2 (0.80) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Trifluperidol SCHEMBL4122414 | 0.90 | ABCB11 (0.73) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Haloperidol SCHEMBL9507217 | 0.89 | DRD2 (0.92) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Haloperidol SCHEMBL5070670 | 0.89 | DRD2 (1.00) | DRD2ADRA1ADRD3DRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629482-B2 | Syringe shock absorber for use in an injection device | ANTARES PHARMA, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12629483-B2 | Syringe shock absorber for use in an injection device | ANTARES PHARMA, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12576213-B2 | Multiple dosage injector with rack and pinion dosage system having ram that includes a lockout protrusion | ANTARES PHARMA, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260034313-A1 | SYRINGE SHOCK ABSORBER FOR USE IN AN INJECTION DEVICE | ANTARES PHARMA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260034303-A1 | Needle Assisted Injection Device Having Reduced Trigger Force | ANTARES PHARMA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260034302-A1 | Needle Assisted Injection Device Having Reduced Trigger Force | ANTARES PHARMA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4585241-A2 | A SYRINGE SHOCK ABSORBER FOR USE IN AN INJECTION DEVICE | Antares Pharma, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12318581-B2 | Needle assisted injection device having reduced trigger force | ANTARES PHARMA, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| EP-3984572-B1 | A SYRINGE SHOCK ABSORBER FOR USE IN AN INJECTION DEVICE | ANTARES PHARMA INC (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20250050037-A1 | SYRINGE SHOCK ABSORBER FOR USE IN AN INJECTION DEVICE | ANTARES PHARMA, INC. (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2014164786-A1 | DOSAGE INJECTOR WITH PINION SYSTEM | MADSEN PATRICK (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140257197-A1 | MULTIPLE DOSAGE INJECTOR WITH RACK AND PINION DOSAGE SYSTEM | ANTARES PHARMA, INC. | 2014-09-11 | — | — | US | disclosed |
| WO-2014124464-A1 | NEEDLE ASSISTED JET INJECTION DEVICE HAVING REDUCED TRIGGER FORCE | TRAVANTY MICHAEL (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20130331788-A1 | INJECTION DEVICE WITH CAMMED RAM ASSEMBLY | ANTARES PHARMA, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-20130317431-A1 | NEEDLE ASSISTED JET INJECTION DEVICE HAVING REDUCED TRIGGER FORCE | ANTARES PHARMA, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2013169800-A1 | INJECTION DEVICE WITH CAMMED RAM ASSEMBLY | ANTARES PHARMA, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013169804-A1 | NEEDLE ASSISTED JET INJECTION DEVICE HAVING REDUCED TRIGGER FORCE | ANTARES PHARMA, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20090036389-A1 | Polymeric Micelle Formulations of Hydrophobic Compounds and Methods | ABBOTT LABORATORIES (US) | 2009-02-05 | — | — | US | disclosed |
| US-20040005351-A1 | Polymeric micelle formulations of hydrophobic compounds and methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-08 | — | — | US | disclosed |
| WO-2003082303-A1 | POLYMERIC MICELLE FORMULATIONS OF HYDROPHOBIC COMPOUNDS AND METHODS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034303-A1 | Needle Assisted Injection Device Having Reduced Trigger Force | TIMM44, SARAF, TIMM50 | DRD2 2480/4885DRD3 3160/4885DRD4 4148/4885 |
| US-12576213-B2 | Multiple dosage injector with rack and pinion dosage system having ram that includes a lockout protrusion | RACK1, DYNLL1, TRAF6 | DRD2 1444/4885DRD3 903/4885DRD4 1203/4885 |
| US-12318581-B2 | Needle assisted injection device having reduced trigger force | TIMM44, SARAF, TIMM10 | DRD2 3204/4885DRD3 3061/4885DRD4 3792/4885 |
| US-20260034313-A1 | SYRINGE SHOCK ABSORBER FOR USE IN AN INJECTION DEVICE | CRH, SSTR5, CLPP | DRD2 2132/4885DRD3 2790/4885DRD4 2368/4885 |
| US-20260034302-A1 | Needle Assisted Injection Device Having Reduced Trigger Force | TIMM44, NPY4R, P2RY11 | DRD2 1525/4885DRD3 1690/4885DRD4 2380/4885 |
| US-12629482-B2 | Syringe shock absorber for use in an injection device | SLC6A4, SLC47A2, ABCB11 | DRD2 2179/4885DRD3 2582/4885DRD4 2233/4885 |
| US-12629483-B2 | Syringe shock absorber for use in an injection device | SLC6A4, SSTR4, SLC6A2 | DRD2 1570/4885DRD3 1695/4885DRD4 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.